Maintenance Infos

Publications for Andreesen, R

Navigate back| Up a level
Export as
Group by:
Jump to:
Number of items: 3.


Engert, A; Haverkamp, H; Kobe, C; Markova, J; Renner, C; Ho, A; Zijlstra, J; Král, Z; Fuchs, M; Hallek, M; Kanz, L; Döhner, H; Dörken, B; Engel, N; Topp, M; Klutmann, S; Amthauer, H; Bockisch, A; Kluge, R; Kratochwil, C; Schober, O; Greil, R; Andreesen, R; Kneba, M; Pfreundschuh, M; Stein, H; Eich, H T; Müller, R P; Dietlein, M; Borchmann, P; Diehl, V (2012). Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet, 379(9828):1791-1799.


Landfried, K; Bataille, F; Rogler, G; Brenmoehl, J; Kosovac, K; Wolff, D; Hilgendorf, I; Hahn, J; Edinger, M; Hoffmann, P; Obermeier, F; Schoelmerich, J; Andreesen, R; Holler, E (2010). Recipient NOD2/CARD15 status affects cellular infiltrates in human intestinal graft-versus-host disease. Clinical and Experimental Immunology, 159(1):87-92.


Holler, E; Rogler, G; Brenmoehl, J; Hahn, J; Greinix, H; Dickinson, A M; Socie, G; Wolff, D; Finke, J; Fischer, G; Jackson, G; Rocha, V; Hilgendorf, I; Eissner, G; Marienhagen, J; Andreesen, R (2008). The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation. International Journal of Immunogenetics, 35(4-5):381-384.

This list was generated on Wed Jul 18 13:33:26 2018 CEST.